Oncology CAR-T has a geography problem The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now.
Oncology Expanding the haematology toolkit: Insights and operational ... With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.
News BMS's Breyanzi is first CAR-T for marginal zone lymphoma Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.
Oncology Breaking barriers to CAR T-cell therapy: The vision for expa... Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.
R&D Purity, potency, and safety – affordably – in stem cell ther... In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s
News JPM: Precision Bio continues offload of CAR-T rights Precision BioSciences has agreed to a second licensing deal for its ‘off-the-shelf’ CAR-T therapy azer-cel, as it switches focus to developing in vivo applications of its
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
